

# Sigurd Broesby-Olsen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3141771/sigurd-broesby-olsen-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46  
papers

1,708  
citations

19  
h-index

41  
g-index

50  
ext. papers

2,105  
ext. citations

5.4  
avg, IF

4.28  
L-index

#	Paper	IF	Citations
46	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 35-45	11.5	209
45	Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 509-519	4	173
44	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. <i>Leukemia</i> , <b>2015</b> , 29, 1223-32	10.7	164
43	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , <b>2017</b> , 77, 1261-1270	10.1	162
42	Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 69, 1267-74	9.3	119
41	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 1125-1133.e1	5.4	106
40	Epidemiology of systemic mastocytosis in Denmark. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 521-8	4.5	104
39	Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 493-8	7.1	72
38	Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 73, 230-238	9.3	59
37	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , <b>2019</b> , 180, 44-51	3.7	46
36	Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 262-4	11.5	44
35	Treatment strategies in mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , <b>2014</b> , 34, 433-47	3.3	43
34	Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1069-1075	7.1	40
33	Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. <i>European Journal of Haematology</i> , <b>2012</b> , 89, 42-6	3.8	38
32	KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 132, 723-728	11.5	36
31	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. <i>Lancet, The</i> , <b>2013</b> , 382, 1380	4.0	31
30	Patterns of anaphylaxis after diagnostic workup: A follow-up study of 226 patients with suspected anaphylaxis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 72, 1944-1952	9.3	25

29	Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 72, 1737-1743	9.3	24
28	Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 130, 806-8	11.5	22
27	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 2139-2144	5.4	17
26	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.. <i>HemaSphere</i> , <b>2021</b> , 5, e646	0.3	16
25	Exercise-induced anaphylaxis: causes, consequences, and management recommendations. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 265-273	5.1	16
24	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 300-306	11.5	15
23	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. <i>Acta Dermato-Venereologica</i> , <b>2016</b> , 96, 602-12	2.2	11
22	Definition, aims, and implementation of GA LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 2115-2123	9.3	10
21	Atopic diseases and type I sensitization from adolescence to adulthood in an unselected population (TOACS) with focus on predictors for allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 74, 308-317	9.3	10
20	Multiple self-healing squamous epithelioma of Ferguson-Smith: observations in a Danish family covering four generations. <i>Acta Dermato-Venereologica</i> , <b>2008</b> , 88, 52-6	2.2	9
19	Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis. <i>European Journal of Haematology</i> , <b>2016</b> , 96, 381-8	3.8	8
18	Pediatric Expression of Mast Cell Activation Disorders. <i>Immunology and Allergy Clinics of North America</i> , <b>2018</b> , 38, 365-377	3.3	8
17	KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis. <i>Dermatology</i> , <b>2013</b> , 226, 233-7	4.4	8
16	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 3918-3928	5.4	8
15	Everyday life and mastocytosis from a patient perspective-a qualitative study. <i>Journal of Clinical Nursing</i> , <b>2019</b> , 28, 1114-1124	3.2	7
14	It looks like childhood eczema but is it?. <i>Clinical and Experimental Allergy</i> , <b>2019</b> , 49, 744-753	4.1	6
13	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. <i>American Journal of Human Genetics</i> , <b>2021</b> , 108, 284-294	11	6
12	Comparison of gDNA-based versus mRNA-based KIT D816V mutation analysis reveals large differences between blood and bone marrow in systemic mastocytosis. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 330-332	4.5	5

11	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2022</b> ,	5.4	5
10	Clinical validation of a new commercial highly sensitive KIT D816V mutation analysis in mastocytosis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 1489-1491	9.3	4
9	Platelet-activating factor decreases skin keratinocyte tight junction barrier integrity. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 1725-1728.e3	11.5	4
8	Adherence to adrenaline autoinjector prescriptions in patients with anaphylaxis. <i>Clinical and Translational Allergy</i> , <b>2019</b> , 9, 59	5.2	4
7	Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis. <i>Blood</i> , <b>2020</b> , 136, 41-42	2.2	3
6	A child with mastocytosis and lymphomatoid papulosis. <i>Clinical Case Reports (discontinued)</i> , <b>2016</b> , 4, 517-0.7		3
5	Towards rational diagnostics in mastocytosis: clinical validation of sensitive KIT D816V mutation analysis of unfractionated whole-blood. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 268-270	1.9	2
4	Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. <i>Blood</i> , <b>2019</b> , 134, 2950-2950	2.2	2
3	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , <b>2021</b> , 43, e19-e25	2.5	2
2	Venom anaphylaxis can mimic other serious conditions and disclose important underlying disease. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2018</b> , 120, 338-339	3.2	1
1	Mastocytosis: Overview of Diagnosis and Classification <b>2020</b> , 23-34		